Marlyn Fernandez, MD
Endocrinology, Diabetes & Metabolism · Glen Ridge, NJNPI 1124253752
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,162 of the $18,883 with a category attached, or 75.0%. 36 manufacturers reported payments, led by Novo Nordisk at 44.6% of the total. Reporting peaked in 2019 at $10,092 and has fallen 86.6% since, to $1,350 in 2025.
Across 293 payments — averaging $64.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$8K
- AstraZeneca$7K
- Corcept Therapeutics$624
- Lilly USA, LLC$457
- Medtronic$259
- Sanofi-aventis U.S. LLC$223
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$14,16275%
- Food & beverage$4,65325%
- Education$80%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 92 | $8,430 |
| AstraZeneca(2 entities) | 24 | $7,293 |
| Corcept Therapeutics | 27 | $624 |
| Lilly USA, LLC | 39 | $457 |
| Medtronic(2 entities) | 7 | $259 |
| Sanofi-aventis U.S. LLC | 14 | $223 |
| Abbott | 8 | $164 |
| Merck | 11 | $151 |
| Radius Health, Inc. | 8 | $134 |
| GSK | 7 | $105 |
| Mannkind Corporation | 4 | $104 |
| Johnson & Johnson(2 entities) | 5 | $93 |
| Insulet Corporation | 5 | $86 |
| Boehringer Ingelheim | 6 | $86 |
| Amgen | 5 | $82 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Alvogen Inc | 4 | $74 |
| Tandem Diabetes Care, Inc. | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Exact Sciences | 1 | $32 |
| Chiesi USA, Inc. | 1 | $28 |
| Cequr Corporation | 1 | $25 |
| BETA Bionics, Inc. | 1 | $25 |
| Sequel Med Tech, LLC | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| AbbVie | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Valeritas, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,883 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 201 | $331,002 |
| MounjaroTirzepatide | 181 | $296,035 |
| JardianceEmpagliflozin | 120 | $157,651 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 101 | $130,133 |
| TrulicityDulaglutide | 57 | $107,457 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 109 | $105,753 |
| JanuviaSitagliptin Phosphate | 77 | $84,660 |
| FarxigaDapagliflozin Propanediol | 68 | $84,612 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $75,003 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 52 | $66,003 |
| Xigduo XrDapaglifloz Propaned/Metformin | 46 | $51,398 |
| SynjardyEmpagliflozin/Metformin Hcl | 54 | $50,035 |
| TradjentaLinagliptin | 33 | $38,929 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $35,582 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $29,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta | $86 | $462,997380 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $457 | $405,695250 claims |
| Novo NordiskOzempic | $8,430 | $331,002201 claims |
| MerckJanumet Xr, Januvia, Janumet | $151 | $225,995212 claims |
| AstraZenecaFarxiga | $7,293 | $84,61268 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $223 | $28,08221 claims |
| AbbVieSynthroid | $15 | $4,27649 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $4,166418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Glen Ridge
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.